Novel computerized neurocognitive test battery is sensitive to cancer-related cognitive deficits in survivors

Plasma levels of interleukin‐6 mediate neurocognitive performance in older breast cancer survivors: The Thinking and Living With Cancer study

“…Second, despite significant findings for APE, especially with the Trail Making B test, there were no differences in LM or self‐reported cognition between survivors and controls, which limited the ability to test pathways for these aspects of CRCD. In our past studies with the full TLC sample, 2 our LM battery has not been as sensitive as APE tests to detect differences in groups, which suggests that more sensitive neurocognitive testing approaches may be needed to better understand the nature of CRCD 44,45 . Third, although women in our sample were representative of the communities served by our tertiary academic medical centers and their community affiliates, they were predominantly White, non‐Hispanic, and well educated, which limits external generalizability.…”

“…In our past studies with the full TLC sample, 2 our LM battery has not been as sensitive as APE tests to detect differences in groups, which suggests that more sensitive neurocognitive testing approaches may be needed to better understand the nature of CRCD. 44,45 Third, although women in our sample were representative of the communities served by our tertiary academic medical centers and their community affiliates, they were predominantly White, non-Hispanic, and well educated, which limits external generalizability. It will be critical to replicate our results in more diverse samples, especially in groups with lifetime experiences associated with increased chronic inflammation.…”

A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects

“…For example, evaluating intraindividual variability in performance within and between tasks appears to be a more sensitive approach to identify subtle cognitive changes experienced during chemotherapy. [45][46][47][48][49] In the future RCT, we also plan to facilitate interpretation of observed cognitive changes using reliable change indices 50,51 and enhance sensitivity to detect an effect using "gatekeeper" approaches, [52][53][54] a method of condensing results from multiple cognitive tests into composite cognitive domain outcomes that has been demonstrated to increase reliability and precision of treatment estimates, improve power, and minimize Type I error, and, thus, is being increasingly utilized in CRCI and other populations. 22,[55][56][57][58] We also found promising early data as it relates to patient-reported cognitive function.…”

Assessing cancer-related cognitive function in the context of everyday life using ecological mobile cognitive testing: A protocol for a prospective quantitative study

“…These platforms can ease burdens related to in-person data collection for both participants and researchers and may be more sensitive to CRCI detection than paper and pencil testing. 70 , 74 However, they are typically administered in place of traditional neuropsychological testing and under similar circumstances (i.e. in quiet/non-distracting environments, with administrator oversite via phone or videoconference) and at similar frequencies (i.e.…”